2024 Partners


Lead Partner

At Seromyx Systems we harness the power of cutting-edge technology, including high-throughput cell and bead-based assays coupled with machine learning computational analysis, to measure and understand the intricate functions of antibodies in the immune system.

Our platform, developed by leading experts from the Ragon Institute with Harvard, MIT and Massachusetts General Hospital, empowers pharmaceutical and biotechnology companies to design future monoclonal and immunotherapies with unmatched precision. By deciphering the complex interactions between antibodies and innate immune cells, we identify the key functions driving efficacy in immune responses.

Through our comprehensive analysis, we help our clients unlock critical insights, determining the most effective combinations of antibody functions to combat pathogens, infected cells, or tumor cells. Our mission is to revolutionize the field of serology and drive the development of tailored monoclonal and immunotherapies that save lives and improve global health.



Expertise Partner

genOway is a biotechnology company with over 20 years of expertise in the development of physiologically relevant translational preclinical models.

The company has developed a catalog of humanized, “off-the-shelf” cell and mouse models for immuno-oncology to accelerate research into the pathophysiology of cancer and enable the assessment of new therapeutic agents.

Founded in 1999, genOway currently operates in more than 28 countries with 380 academic institutions and 170 life science companies, including 17 of the top 20 pharmaceutical companies.


Retham Technologies™

Innovation Partner

Platelet activation leading to thrombosis and/or thrombocytopenia is a risk with IgG antibody-based therapeutics. Obtaining platelets and assessing platelet activation endpoints can be challenging. Now you can de-risk IgG therapeutic candidates with help from the platelet experts at Retham Technologies. We have developed ground-breaking technology for on-demand evaluation of platelet activation induction by IgGs using RethamTM cryopreserved platelets coupled to an easy activation read-out (ELISA). Partner with Retham to de-risk your valuable IgG therapeutic candidates!



Exhibition Partner

Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 1,500 biotech and pharma companies worldwide.
Contact us at: info@biointron.com, or +1(732)790-8340